嵌合抗原受体T细胞的应用进展与挑战：第57届美国血液学会年会报道

Progress of chimeric antigen receptor T cells in the treatment of hematologic malignancies：reports from the 57th American Society of Hematology annual meeting

嵌合抗原受体T细胞（CAR-T）是目前最有发展前景的肿瘤免疫疗法之一，在第57届美国血液学会（ASH）年会上受到了极大关注。CAR-T在白血病和淋巴瘤中已经取得显著的疗效，该次大会上的最新研究结果也令人鼓舞。 CAR-T疗法如何与传统的治疗方法、免疫靶点阻断剂以及小分子靶向药物等联合应用，以达到最佳的疗效，也是面临的一个重要任务。文章就CAR-T在血液肿瘤中的应用进展进行介绍。

Chimeric antigen receptor T cells （CAR-T）, one of the most promising cancer immunotherapy, has attracted much attention in the 57th American Society of Hematology （ASH） annual meeting. CAR-T therapy has obtained significant effect on leukemia and lymphoma and the latest research results are also inspiring in the 57th ASH annual meeting. It is an important task that how to combine CAR-T therapy with the traditional methods of treatment and the immune checkpoint blocking antibodies and small-molecule-targeted drugs to achieve the best effect. This paper will review the progress of CAR-T in the treatment of hematologic malignancies.